Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for ELVN
| Stock Name | Enliven Therapeutics Inc. |
| Ticker | ELVN(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US29337E1029 |
Show aggregate ELVN holdings
News associated with ELVN
- Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.20
- Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) has earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the […] - 2025-08-08 02:42:46
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in Stock
- Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares in the company, valued […] - 2025-07-22 07:14:55
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares
- Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $22.66, for a total transaction of $22,660.00. Following the transaction, the chief financial officer directly owned 23,000 shares of the company’s […] - 2025-07-15 06:21:06
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Buy” from Brokerages
- Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a […] - 2025-07-11 05:23:02
- Enliven Therapeutics (NASDAQ:ELVN) Trading 7.9% Higher Following Analyst Upgrade
- Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price was up 7.9% on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. Approximately 171,529 shares traded […] - 2025-07-04 02:24:46
- Exchange Traded Concepts LLC Reduces Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
- Exchange Traded Concepts LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,055 shares of the company’s stock after selling 1,428 shares during the period. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $119,000 as of its most […] - 2025-06-24 04:38:52
- Rhumbline Advisers Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
- Rhumbline Advisers raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 4.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 52,502 shares of the company’s stock after acquiring an additional 2,466 shares during the period. Rhumbline Advisers’ holdings in Enliven Therapeutics were worth $1,033,000 […] - 2025-06-20 04:22:47
- Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock
- Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 138.53% from the stock’s […] - 2025-06-18 03:08:46
- Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group
- Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […] - 2025-06-18 03:08:45
- Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade
- Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven […] - 2025-06-17 02:08:49
- Two Sigma Investments LP Decreases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
- Two Sigma Investments LP lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 33.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its […] - 2025-06-11 04:30:51
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,036 shares of the company’s stock after purchasing an additional 718 shares during the […] - 2025-05-30 04:55:02
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Buy” by Brokerages
- Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-27 05:26:58
- Voya Investment Management LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
- Voya Investment Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,702 shares of the company’s stock after selling 945 shares during the quarter. Voya […] - 2025-05-13 05:22:51
- Marshall Wace LLP Has $931,000 Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
- Marshall Wace LLP cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 70.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,382 shares of the company’s stock after selling 96,624 shares during the quarter. Marshall Wace LLP’s holdings in Enliven Therapeutics were worth $931,000 at the end […] - 2025-05-01 04:50:53
- ExodusPoint Capital Management LP Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
- ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $200,000. Other hedge funds have also added to or reduced […] - 2025-04-15 04:39:25
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Fmr LLC
- Fmr LLC grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned about 0.13% […] - 2025-04-14 05:48:47
- Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Holdings Lowered by Corebridge Financial Inc.
- Corebridge Financial Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 1,321 shares during the quarter. […] - 2025-04-10 04:49:04
- Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling
- Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price traded down 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares were traded during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock […] - 2025-04-03 02:44:44
- Tuesday's ETF Movers: BLOK, IHE
- In trading on Tuesday, the Amplify Transformational Data Sharing ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Core Scientific, up about 8.1% and shares of Applied Digital, up about 6.6% on the da - 2025-04-01 13:04:57
- Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says
- Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective lifted by HC Wainwright from $37.00 to $39.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set […] - 2025-03-24 04:13:03
iShares MSCI World Small Cap UCITS ETF USD (Acc) ELVN holdings
| Date | Number of ELVN Shares Held | Base Market Value of ELVN Shares | Local Market Value of ELVN Shares | Change in ELVN Shares Held | Change in ELVN Base Value | Current Price per ELVN Share Held | Previous Price per ELVN Share Held |
|---|
| 2025-10-15 (Wednesday) | 20,111 | USD 437,012 | USD 437,012 | | | | |
| 2025-10-10 (Friday) | 19,979 | USD 415,963 | USD 415,963 | | | | |
| 2025-10-08 (Wednesday) | 19,979 | USD 405,973 | USD 405,973 | | | | |
| 2025-10-07 (Tuesday) | 19,979 | USD 401,778 | USD 401,778 | 90 | USD -1,969 | USD 20.11 | USD 20.3 |
| 2025-10-06 (Monday) | 19,889 | USD 403,747 | USD 403,747 | 0 | USD 13,724 | USD 20.3 | USD 19.61 |
| 2025-10-03 (Friday) | 19,889 | USD 390,023 | USD 390,023 | 0 | USD -6,166 | USD 19.61 | USD 19.92 |
| 2025-10-02 (Thursday) | 19,889 | USD 396,189 | USD 396,189 | 0 | USD 1,890 | USD 19.92 | USD 19.825 |
| 2025-10-01 (Wednesday) | 19,889 | USD 394,299 | USD 394,299 | 0 | USD -12,829 | USD 19.825 | USD 20.47 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ELVN by Blackrock for IE00BF4RFH31
Show aggregate share trades of ELVN| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 90 | | | 20.110* | | 19.89 |
| 2025-09-08 | SELL | -176 | | | 20.020* | | 0.00 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ELVN
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 255,512 | 2,440 | 367,300 | 69.6% |
| 2025-09-18 | 205,742 | 0 | 372,476 | 55.2% |
| 2025-09-17 | 162,926 | 1,997 | 258,660 | 63.0% |
| 2025-09-16 | 210,614 | 0 | 354,409 | 59.4% |
| 2025-09-15 | 158,968 | 15 | 285,258 | 55.7% |
| 2025-09-12 | 150,977 | 0 | 331,828 | 45.5% |
| 2025-09-11 | 96,060 | 0 | 385,686 | 24.9% |
| 2025-09-10 | 47,949 | 6 | 151,232 | 31.7% |
| 2025-09-09 | 131,883 | 0 | 239,214 | 55.1% |
| 2025-09-08 | 196,306 | 8,811 | 347,785 | 56.4% |
| 2025-09-05 | 63,256 | 0 | 131,309 | 48.2% |
| 2025-09-04 | 78,435 | 0 | 146,468 | 53.6% |
| 2025-09-03 | 105,005 | 0 | 189,634 | 55.4% |
| 2025-09-02 | 92,210 | 308 | 154,107 | 59.8% |
| 2025-08-29 | 152,705 | 246 | 324,867 | 47.0% |
| 2025-08-28 | 113,372 | 0 | 320,884 | 35.3% |
| 2025-08-27 | 114,853 | 2,880 | 257,350 | 44.6% |
| 2025-08-26 | 36,937 | 0 | 145,789 | 25.3% |
| 2025-08-25 | 150,668 | 0 | 277,238 | 54.3% |
| 2025-08-22 | 164,536 | 0 | 493,351 | 33.4% |
| 2025-08-21 | 208,223 | 1,982 | 440,282 | 47.3% |
| 2025-08-20 | 69,564 | 1,006 | 132,987 | 52.3% |
| 2025-08-19 | 42,058 | 3,410 | 78,032 | 53.9% |
| 2025-08-18 | 52,776 | 3,411 | 113,030 | 46.7% |
| 2025-08-15 | 49,843 | 607 | 137,044 | 36.4% |
| 2025-08-14 | 60,767 | 0 | 121,823 | 49.9% |
| 2025-08-13 | 77,834 | 0 | 145,516 | 53.5% |
| 2025-08-12 | 76,411 | 0 | 165,024 | 46.3% |
| 2025-08-11 | 49,374 | 0 | 80,191 | 61.6% |
| 2025-08-08 | 148,399 | 100 | 336,540 | 44.1% |
| 2025-08-07 | 75,044 | 2,200 | 122,751 | 61.1% |
| 2025-08-06 | 123,117 | 20 | 222,055 | 55.4% |
| 2025-08-05 | 103,501 | 0 | 245,375 | 42.2% |
| 2025-08-04 | 36,934 | 0 | 99,774 | 37.0% |
| 2025-08-01 | 100,865 | 0 | 290,379 | 34.7% |
| 2025-07-31 | 72,665 | 0 | 189,293 | 38.4% |
| 2025-07-30 | 83,029 | 0 | 128,492 | 64.6% |
| 2025-07-29 | 41,527 | 0 | 133,286 | 31.2% |
| 2025-07-28 | 44,820 | 1,104 | 199,290 | 22.5% |
| 2025-07-25 | 38,438 | 6 | 75,237 | 51.1% |
| 2025-07-24 | 72,747 | 28 | 125,300 | 58.1% |
| 2025-07-23 | 27,864 | 0 | 77,643 | 35.9% |
| 2025-07-22 | 50,068 | 0 | 117,137 | 42.7% |
| 2025-07-21 | 63,682 | 7,051 | 239,269 | 26.6% |
| 2025-07-18 | 39,727 | 258 | 109,464 | 36.3% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.